CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2018--
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), granted
eight newly-hired employees options to purchase an aggregate of 37,400
shares of Akebia’s common stock on July 31, 2018, as inducements
material to each such employee’s entering into employment with Akebia.
The options were granted in accordance with Nasdaq Listing Rule
The options have an exercise price of $10.30 per share, which is equal
to the closing price of Akebia’s common stock on the grant date. Each
stock option vests over four years, with 25% of the shares vesting on
the first anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee’s continued service with the company. Each stock option has a
10-year term and is subject to the terms and conditions of the company’s
Inducement Award Program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. For more information, please visit our website at www.akebia.com,
which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005539/en/
Source: Akebia Therapeutics, Inc.
John Garabo, 617-844-6130